| Vera Therapeutics: Huge Catalyst Upcoming For Kidney Disease Drug |
I am maintaining my 'Hold' rating on Vera Therapeutics from January 2024 despite initial strong stock gains and positive Phase 2b data for atacicept, before a collapse in stock value. In my last note, I cited high short interest, lack of other assets, and long timeline for approval as key reasons for caution. Vera's pivotal Phase 3 trial data is likely to be shared in the next month, however, presenting a potentially momentous catalyst, and an approval shot in 2026. |
seekingalpha.com |
2025-05-15 18:46:22 |
Czytaj oryginał (ang.) |
| Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
BRISBANE, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on May 5, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 111,750 shares of Class A common stock and restricted stock units (RSUs) for 62,575 shares of Class A common stock to eleven (11) new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2025-05-09 20:05:00 |
Czytaj oryginał (ang.) |
| Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results |
On track to announce the primary endpoint results from the atacicept pivotal Phase 3 ORIGIN trial in IgA Nephropathy (IgAN) in 2Q 2025; planning for Biologics License Application (BLA) submission for atacicept accelerated approval to the U.S. FDA in 4Q 2025 Expanded atacicept development program across multiple autoimmune kidney diseases is underway BRISBANE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business highlights and financial results for the first quarter ended March 31, 2025. |
globenewswire.com |
2025-05-06 12:00:00 |
Czytaj oryginał (ang.) |
| Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
BRISBANE, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on April 3, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 211,250 shares of Class A common stock and restricted stock units (RSUs) for 105,125 shares of Class A common stock to sixteen (16) new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2025-04-09 20:05:00 |
Czytaj oryginał (ang.) |
| Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN |
On track to announce primary endpoint result from ORIGIN 3 trial this quarter (2Q 2025) U.S. FDA BLA submission for accelerated approval planned for 2H 2025 BRISBANE, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that it has completed full enrollment in the pivotal ORIGIN Phase 3 trial of atacicept in patients with IgA Nephropathy (IgAN). |
globenewswire.com |
2025-04-03 12:00:00 |
Czytaj oryginał (ang.) |
| Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
BRISBANE, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on March 6, 2025, the Compensation Committee granted inducement awards consisting of a non-qualified stock option to purchase 51,500 shares of Class A common stock and restricted stock units (RSUs) for 25,750 shares of Class A common stock to nine (9) new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2025-03-11 18:28:00 |
Czytaj oryginał (ang.) |
| Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference |
BRISBANE, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference, which is taking place in Boston, MA from March 3 – 5, 2025. |
globenewswire.com |
2025-02-27 10:00:00 |
Czytaj oryginał (ang.) |
| Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results |
BRISBANE, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business highlights and financial results for the fourth quarter and full year ended December 31, 2024. |
globenewswire.com |
2025-02-26 10:25:00 |
Czytaj oryginał (ang.) |
| Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
BRISBANE, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on February 8, 2025, the Compensation Committee granted inducement awards consisting of a non-qualified stock option to purchase 157,750 shares of Class A common stock and restricted stock units (RSUs) for 78,875 shares of Class A common stock to seventeen (17) new employees under the Inducement Plan. |
globenewswire.com |
2025-02-13 18:05:00 |
Czytaj oryginał (ang.) |
| Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
BRISBANE, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on January 8, 2025, the Compensation Committee granted inducement awards consisting of a non-qualified stock option to purchase 35,250 shares of Class A common stock and restricted stock units (RSUs) for 17,625 shares of Class A common stock to six new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2025-01-14 18:05:00 |
Czytaj oryginał (ang.) |
| Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference |
BRISBANE, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will present at the 43rd Annual J.P. Morgan Healthcare Conference, which is taking place in San Francisco, CA from January 12 – 16, 2025. The management team will also participate in one-on-one investor meetings. |
globenewswire.com |
2025-01-07 18:05:00 |
Czytaj oryginał (ang.) |
| Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
BRISBANE, Calif., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on December 3, 2024, the Compensation Committee granted inducement awards consisting of a non-qualified stock option to purchase 171,750 shares of Class A common stock and restricted stock units (RSUs) for 86,625 shares of Class A common stock to seventeen new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2024-12-09 20:29:00 |
Czytaj oryginał (ang.) |
| Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
BRISBANE, Calif., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on November 18, 2024, the Compensation Committee of Vera's Board of Directors granted inducement awards consisting of a non-qualified stock option to purchase 108,000 shares of Class A common stock and restricted stock units (RSUs) for 53,000 shares of Class A common stock to Jason S. Carter, Vera's new Chief Legal Officer, under Vera's 2024 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employee's employment in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2024-11-22 18:05:00 |
Czytaj oryginał (ang.) |
| Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
Brisbane, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on November 4, 2024, the Compensation Committee granted inducement awards consisting of a non-qualified stock option to purchase 54,050 shares of Class A common stock and restricted stock units (RSUs) for 27,025 shares of Class A common stock to seven new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2024-11-11 18:05:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Think Vera Therapeutics (VERA) Could Surge 27.26%: Read This Before Placing a Bet |
The consensus price target hints at a 27.3% upside potential for Vera Therapeutics (VERA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2024-11-11 13:00:31 |
Czytaj oryginał (ang.) |
| Vera Therapeutics to Participate at Upcoming Investor Conferences |
BRISBANE, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will present and participate in one-on-one meetings at upcoming investor conferences. |
globenewswire.com |
2024-11-08 18:05:00 |
Czytaj oryginał (ang.) |
| Vera Therapeutics to Participate at Upcoming Investor Conferences |
BRISBANE, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will present and participate in one-on-one meetings at upcoming investor conferences. |
globenewswire.com |
2024-11-08 10:00:00 |
Czytaj oryginał (ang.) |
| Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock |
BRISBANE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced the pricing of an underwritten public offering of 7,142,858 shares of its Class A common stock at a price to the public of $42.00 per share. |
globenewswire.com |
2024-10-29 22:21:00 |
Czytaj oryginał (ang.) |
| Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock |
BRISBANE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced its plans to commence a public offering, subject to market and other conditions, to issue and sell $300.0 million of shares of its Class A common stock. All of the shares are being offered by Vera. |
globenewswire.com |
2024-10-28 19:37:00 |
Czytaj oryginał (ang.) |
| Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years |
On Saturday, Vera Therapeutics Inc. VERA released data from its ORIGIN Phase 2b trial of atacicept in immunoglobulin A nephropathy (IgAN), which showed stabilized kidney function through 96 weeks of long-term follow-up. |
benzinga.com |
2024-10-28 12:33:45 |
Czytaj oryginał (ang.) |